Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
Recruiting · Locations being confirmed
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •Adults ages 18 to 75 with a diagnosis of asthma for at least 6 months before screening, and diagnosed before age 50.
- •People who do not smoke, or who used to smoke (non-smokers or ex-smokers).
- •Body mass index (BMI) between 18.0 and 35.0 kg/m2 (inclusive).
- •Asthma has been on stable treatment for at least 4 weeks before screening, using low/medium doses of inhaled steroid (ICS) alone or low/medium doses of ICS plus LABA (a long-acting “beta-2” asthma medicine).
- •At screening and at randomization, asthma control is “controlled or partly controlled” with ACQ-7 score < 1.5 (ACQ-7 is an asthma control questionnaire).
🚫 You may not be able to join if…
- •People with a history of near-fatal asthma or asthma hospitalization/ER/intensive care in the 6 months before screening.
- •People who had a recent asthma worsening that needed steroid tablets/shots (systemic corticosteroids) or an ER visit/hospitalization for asthma within 3 months before screening or during the run-in period.
- •People with non-persistent asthma where asthma is only exercise-induced or seasonal and does not require daily asthma control medicine.
- •People using certain asthma treatments, including high-dose ICS, LAMA (long-acting muscarinic antagonist), systemic/depot/slow-release corticosteroids within 12 weeks, other asthma medicines (like cromolyn or leukotriene modifiers) within 4 weeks, or any biologic asthma therapy within 6 months.
- •People with other respiratory disorders than asthma, or who have had lung surgery/resection, lung cancer, active cancer (except lung cancer history is specifically addressed), or clinically significant cardiovascular conditions.
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults roughly 18–75
- ✓Have Obesity / overweight or COPD (chronic lung disease) or Asthma
- !Some conditions may not be a fit: Heart / cardiovascular disease
What to expect, step by step
- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
If you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
Has this treatment been tested before?
Yes. This treatment has already been through earlier human studies for safety before reaching this stage.
What you need to know before you apply
What is this study testing?+
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.
Is it safe? Who makes sure of that?+
This is a mid-stage study (Phase 2), looking at safety and whether the treatment works. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
Do I have to stop taking my current medications?+
It depends on the study. Some let you stay on your current medications and some ask you to adjust them. Never stop a medication on your own — the study team will review everything with you first.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. Some studies also pay for your time; the coordinator can tell you if this one does. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Some requirements (like specific lab values or timing) are confirmed directly by the study team, not by us.
Source: ClinicalTrials.gov · NCT07301736 · Locations: being confirmed